Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 330

1.

Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.

Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A.

J Hepatol. 2007 Oct;47(4):499-505. Epub 2007 May 24.

PMID:
17560680
2.

An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.

Sharma P, Kumar A, Shrama BC, Sarin SK.

Am J Gastroenterol. 2008 Jul;103(7):1689-97. doi: 10.1111/j.1572-0241.2008.01828.x. Epub 2008 Jun 28.

PMID:
18557715
3.

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.

Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J.

Hepatology. 2002 Oct;36(4 Pt 1):941-8.

PMID:
12297842
4.

Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.

Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF.

Eur J Gastroenterol Hepatol. 2002 Feb;14(2):153-8.

PMID:
11981339
5.

Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.

Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, Lebrec D, Valla DC, Moreau R.

J Gastroenterol Hepatol. 2002 Aug;17(8):882-8.

PMID:
12164964
6.

Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.

Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK.

J Gastroenterol Hepatol. 2003 Feb;18(2):152-6.

PMID:
12542598
7.

Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.

Sagi SV, Mittal S, Kasturi KS, Sood GK.

J Gastroenterol Hepatol. 2010 May;25(5):880-5. doi: 10.1111/j.1440-1746.2009.06132.x. Epub 2010 Jan 14. Review.

PMID:
20074149
8.

Terlipressin and albumin combination treatment in hepatorenal syndrome.

Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, Demir K, Besisik F, Boztas G, Mungan Z, Kaymakoglu S, Okten A.

Hepatogastroenterology. 2003 Dec;50 Suppl 2:ccciii-cccv.

PMID:
15244209
9.

Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.

Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P; TAHRS Investigators.

Gastroenterology. 2008 May;134(5):1352-9. doi: 10.1053/j.gastro.2008.02.024. Epub 2008 Feb 14.

PMID:
18471512
10.

Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.

Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, Sharma N, Bhalla A, Chawla YK, Singh V.

Liver Int. 2013 Sep;33(8):1187-93. doi: 10.1111/liv.12179. Epub 2013 Apr 21.

PMID:
23601499
11.

Terlipressin in hepatorenal syndrome: Evidence for present indications.

Rajekar H, Chawla Y.

J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:109-14. doi: 10.1111/j.1440-1746.2010.06583.x. Review.

PMID:
21199521
12.

Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.

Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF.

Gastroenterology. 2002 Apr;122(4):923-30.

PMID:
11910344
13.

Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.

Alessandria C, Debernardi-Venon W, Carello M, Ceretto S, Rizzetto M, Marzano A.

Dig Liver Dis. 2009 Apr;41(4):298-302. doi: 10.1016/j.dld.2008.09.014. Epub 2009 Jan 20.

PMID:
19158001
14.

Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.

Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J.

J Hepatol. 2000 Jul;33(1):43-8.

PMID:
10905585
15.

[Meta-analysis of terlipressin in treatment of hepatorenal syndrome: an update].

Zhang ZF, Yang N, Zhao G, Liu LN, Wang YD, Duan ZJ.

Zhonghua Yi Xue Za Zhi. 2009 Jul 28;89(28):1970-4. Chinese.

PMID:
19950571
16.

Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.

Saner F, Kavuk I, Lang H, Biglarnia R, Frühauf NR, Schäfers RF, Malagó M, Broelsch CE.

Eur J Med Res. 2004 Feb 27;9(2):78-82.

PMID:
15090293
17.

Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.

Testro AG, Wongseelashote S, Angus PW, Gow PJ.

J Gastroenterol Hepatol. 2008 Oct;23(10):1535-40. Epub 2008 Sep 3.

PMID:
17784863
18.

Meta-analysis: terlipressin therapy for the hepatorenal syndrome.

Fabrizi F, Dixit V, Martin P.

Aliment Pharmacol Ther. 2006 Sep 15;24(6):935-44. Review.

19.

Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.

Nassar Junior AP, Farias AQ, D' Albuquerque LA, Carrilho FJ, Malbouisson LM.

PLoS One. 2014 Sep 9;9(9):e107466. doi: 10.1371/journal.pone.0107466. eCollection 2014.

20.

Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.

Muñoz LE, Alcalá EG, Cordero P, Martínez MA, Vázquez NY, Galindo S, Mendoza E, Segura JJ.

Ann Hepatol. 2009 Jul-Sep;8(3):207-11.

PMID:
19841499

Supplemental Content

Support Center